Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Iron Metabolism Parameters At First Trimester and preGnancy outcomE (IMAGE)

1 juni 2017 uppdaterad av: University Hospital, Clermont-Ferrand

Clinical and Biological Predictive Factors of Iron Deficiency Anemia in the Third Trimester of Pregnancy

Iron deficiency anemia is the leading cause of anemia during pregnancy, which can still reach 10 to 20% of pregnant women in developed countries, with potentially serious consequences for the child. Systematic iron supplementation remains controversial.

This study aims to identify in the first trimester of pregnancy clinical and biological predictive factors for the occurrence of iron deficiency anemia in the third trimester of pregnancy.

Studieöversikt

Status

Okänd

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Objectives: The main objective is to determine the prevalence of anemia (Hb ≤ 11 g / dl) in the third trimester of pregnancy (T3) and to identify the predictive factors in the first trimester (T1).

Type of study: Prospective monocentric cohort.

Experimental plan: Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice. Hemoglobin, classical iron balance (ferritin, transferrin saturation coefficient) as well as other original parameters: hepcidin and the soluble transferrin receptor are assayed. Socioeconomic and clinical parameters likely to favor an iron deficiency are sought through validated questionnaires. Nutritional advice, combined with martial supplementation if necessary, is given according to a standardized management protocol resulting from the current international recommendations and validated by an internal committee. The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.

The 2012 WHO's recommendations are in favour of a systematic supplementation of pregnant women. Epidemiological studies show that the anaemia at the end of pregnancy increases the risk of severe anaemia in the postpartum hospital stay and the frequency of transfusions in the mother is multiplied by 9. The quality of life of the mother seems too altered by the anaemia with increased susceptibility to infections, cognitive and emotional disorders in the postpartum period and a decrease of capacity of work and performance. In the human new-born, the anaemia is associated with a risk of prematurity, low weight birth and especially a certain degree of later psycho-motor delay, or even perinatal mortality. Side effects of iron orally, it's cost, make debatable systematic supplementation as interventional studies have given contradictory results in terms of morbidity and mortality infant. In areas where the anaemia prevalence is very high, a systematic supplementation of pregnant by 60 mg of iron (with folic acid) is beneficial in children on clues of psycho-intellectual development at 12, 18 and 24 months while multiple supplementation in micronutrients (containing 30 mg of iron) is not effective. However, systematic supplementation in countries with high socioeconomic level did debate. An Australian study Interventional, controlled, randomized conducted at 430 women showed no efficacy on the intellectual development of children in 4 years, without changing the quality of life of the mother during pregnancy, the authors observing even an increase of abnormal behaviors of the children of the mothers in the Group supplemented iron. In another study, the rational is highly questionable, a treatment by Iron versus placebo was given to pregnant women not anaemic with a high haemoglobin (an average of 14 g/dl): the women who took iron had high blood pressure at the end of pregnancy more and their children had a lower birth for the term weight.

In a developed country such as the France, one can legitimately wonder about the potentially harmful effects of routine iron supplementation for a population of pregnant women mainly not anaemic. In Great Britain of the recently published recommendations are pronounced against a systematic supplementation of iron in pregnant women. Other European authors advocate focused on the rate of ferritin supplementation. However, we are lacking of studies allowing, from clinical criteria and biological precise, to better target pregnant women who could benefit from supplementation of iron in the first quarter.

Studietyp

Observationell

Inskrivning (Förväntat)

865

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Auvergne
      • Clermont-Ferrand, Auvergne, Frankrike, 63003
        • CHU de Clermont-Ferrand

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

15 år till 50 år (Barn, Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The women were screened at the maternity clinic of the gynecology-obstetrics department of CHU Estaing in Clermont-Ferrand, France.

Beskrivning

Inclusion Criteria:

  • Pregnant women in the first trimester between 11SA and 13 SA + 6 days
  • A written agreement is needed

Exclusion Criteria:

  • Women who do not know enough about reading and writing French to answer questionnaires
  • Women under 15 at inclusion

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Pregnant women
Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Hemoglobin value
Tidsram: in the third trimestry of pregnancy
in the third trimestry of pregnancy

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of clinical and biological factors per patient
Tidsram: at the first trimestry of pregnancy
demographics and clinical factors and biological factors (hepcidine, ferritine, RST)
at the first trimestry of pregnancy
Rate of demographics and clinical factors per patient
Tidsram: at the first trimestry of pregnancy
biological factors (hepcidine, ferritine, RST)
at the first trimestry of pregnancy
Rate of biological factors per patient
Tidsram: at the first trimestry of pregnancy
Such as : hepcidine, ferritine, RST
at the first trimestry of pregnancy

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Marc RUIVARD, MD, PhD, CHU de Clermont-Ferrand

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 november 2015

Primärt slutförande (Förväntat)

1 juni 2017

Avslutad studie (Förväntat)

1 januari 2018

Studieregistreringsdatum

Först inskickad

30 maj 2017

Först inskickad som uppfyllde QC-kriterierna

1 juni 2017

Första postat (Faktisk)

5 juni 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 juni 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 juni 2017

Senast verifierad

1 maj 2017

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • CHU-336
  • 2015-A00454-45 (Annan identifierare: 2015-A00454-45)

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Järnbristanemi

Kliniska prövningar på Iron deficiency anemia

3
Prenumerera